The pooled data of the global multicenter trials (WU‐KONG1, WU‐KONG2, and WU‐KONG6) [14] reported at the 2022 WCLC showed that the ORR of sunvozertinib in 84 chemotherapy failure patients with EGFR exon 20ins mutation advanced NSCLC was 52.4% and 44% for patients with brain metastases (n = 25). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.